The Biology and Pharmacology of Glucagon 2.0
A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Endocrinology and Metabolism".
Deadline for manuscript submissions: closed (15 July 2022) | Viewed by 5707
Special Issue Editor
Interests: insulin secretion; beta-cell; glucagon secretion; islet of Langerhans; SGLT2 inhibitor; GLP-1RA; cell replacement therapy; metabolic reprogramming
Special Issue Information
Dear Colleagues,
The discovery of insulin and its pharmacology in 1921 was closely followed by that of glucagon in 1923. However, unlike insulin, glucagon action has been historically stigmatized as diabetogenic and its clinical use restricted to rescue from severe hypoglycemia. Hampered by a short half-life and poor solubility in physiological buffers, this glucocentric view of glucagon has overshadowed that glucagon is a pleiotropic hormone with broad biological action not only in the pancreas and the liver but also in the brain, the heart, the stomach and the white and brown adipose tissue. The diabetogenic reputation of glucagon is urged by reports showing that failure of glucose to suppress glucagon secretion can play a pathophysiological role in the development of type 2 diabetes, while blockade of glucagon can ameliorate hyperglycemia in diabetic patients. Ironically, the diabetogenic view of glucagon has recently been challenged by the generation of pharmacotherapies that along with insulinotropic peptides recruit glucagon receptor agonism into the same entity to treat obesity and type 2 diabetes.
In this Special Issue, we describe the multifaceted nature of glucagon that goes well beyond its role on glucose metabolism. Both original research articles and comprehensive reviews are welcomed.
Prof. Dr. Hisamitsu Ishihara
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- glucagon
- GCGR
- glucagon receptor
- GLP-1
- GLP-1R
- diabetes
- obesity
- insulin
